Mipomersen (INN; trade name Kynamro) is a withdrawn drug that was used to treat homozygous familial hypercholesterolemia and is administered by subcutaneous...
16 KB (865 words) - 02:55, 6 August 2025
Gapmer (section Mipomersen (Kynamro))
Corporation, is administered via subcutaneous injection in the form of a mipomersen sodium solution. The chemical structure is composed of a 20-nucleotide...
10 KB (1,142 words) - 03:00, 6 August 2025
targets. In 2008, Isis and Genzyme entered into a partnered drug candidate mipomersen (Kynamro), intended to treat homozygous familial hypercholesterolemia...
19 KB (1,679 words) - 03:21, 26 May 2025
example of using an asRNA as a therapeutic agent is mipomersen, which was approved by FDA in 2013. Mipomersen was developed to manage the level of low-density...
24 KB (2,997 words) - 05:07, 19 July 2025
e.g., the drugs fomivirsen (Vitravene), oblimersen, alicaforsen, and mipomersen (Kynamro). Further examples of these include: Diazinon Fenitrothion Fenthion...
5 KB (547 words) - 04:26, 14 November 2024
treatment of familial chylomicronaemia syndrome in May 2019. In January 2013 mipomersen (marketed as Kynamro) was approved by the FDA for the treatment of homozygous...
25 KB (2,492 words) - 16:13, 17 July 2025
phosphorothioate antisense oligonucleotides fomivirsen (Vitravene) and mipomersen (Kynamro) for human therapeutic use. In virology, the term "sense" has...
19 KB (2,507 words) - 17:47, 9 July 2025
C10AX08 Policosanol C10AX09 Ezetimibe C10AX10 Alipogene tiparvovec C10AX11 Mipomersen C10AX12 Lomitapide C10AX13 Evolocumab C10AX14 Alirocumab C10AX15 Bempedoic...
4 KB (439 words) - 03:54, 23 December 2024
(Desirudin), for atherothrombosis, Now owned by Bausch Health. Kynamro (Mipomersen), an antisense drug invented by Isis Pharmaceuticals and acquired by Genzyme...
95 KB (9,124 words) - 05:44, 31 July 2025
familial hypercholesterolemia. In January 2013, The US FDA also approved mipomersen, which inhibits the action of the gene apolipoprotein B, for the treatment...
50 KB (5,688 words) - 20:49, 29 May 2025
a novel antioxidant, failed a phase-III trial. Apoprotein-B inhibitor mipomersen (approved by the FDA in 2013 homozygous familial hypercholesterolemia...
12 KB (1,422 words) - 03:55, 18 July 2025
Miochol mioflazine (INN) Miostat mipimazole (INN) mipitroban (INN) Miplyffa mipomersen sodium (USAN) mipragoside (INN) miproxifene (INN) mirabegron (USAN) Miradon...
9 KB (428 words) - 05:43, 27 February 2025
e.g., the drugs fomivirsen (Vitravene), oblimersen, alicaforsen, and mipomersen (Kynamro). Phosphocysteamine, the thiophosphate H3NCH2CH2SPO3Na, is used...
12 KB (1,390 words) - 20:26, 24 July 2025
an ionizable lipid called SM-102. Antisense oligonucleotides (ASOs): Mipomersen (branded as Kynamro), for the treatment of homozygous familial hypercholesterolaemia...
79 KB (8,795 words) - 10:07, 16 July 2025